Inclusion Criteria:

          -  Patients must have a diagnosis of neuroblastoma either by histologic verification of
             neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased
             urinary catecholamines.

          -  Patients must have a history of high-risk neuroblastoma according to COG risk
             classification at the time of study registration. Patients who were initially
             considered low or intermediate-risk, but then reclassified as high-risk are also
             eligible.

          -  Patients must have at least ONE of the following:

               1. Recurrent/progressive disease at any time prior to study enrollment

               2. Refractory disease

               3. Persistent disease

          -  Patients must have at least ONE of the following (lesions may have received prior
             radiation therapy as long as they meet the other criteria listed below):

               1. For recurrent/progressive or refractory disease, at least one MIBG avid bone
                  site.

               2. For persistent disease, If a patient has only 1 or 2 MIBG avid lesions AND a
                  Curie Score of 1-2, then biopsy confirmation of neuroblastoma and/or
                  ganglioneuroblastoma in at least one site present at the time of enrollment (bone
                  marrow, bone, or soft tissue) is required to be obtained at any time point prior
                  to enrollment.

               3. FDG-PET avid tumors: A biopsy confirmation of neuroblastoma and/or
                  ganglioneuroblastoma is required at any time prior to enrollment OR anatomical
                  imaging is required at the time of enrollment consistent with a bone metastasis
                  for at least one FDG-avid bone site.

          -  Any amount of neuroblastoma tumor cells in the bone marrow done at the time of study
             enrollment based on routine morphology with or without immunocytochemistry in at least
             one sample from bilateral aspirates and biopsies.

          -  At least one soft tissue lesion that meets criteria for a TARGET lesion as defined by:

               1. SIZE: Lesion can be accurately measured in at least one dimension with a longest
                  diameter ≥ 10 mm, or for lymph nodes ≥ 15 mm on short axis.

               2. In addition to measurable size, a lesion needs to meet the following criteria:

                    1. MIBG avid. For patients with persistent disease only: If a patient has only
                       1 or 2 MIBG avid lesions ANDa Curie Score of 1 - 2, then biopsy confirmation
                       of neuroblastoma and/or ganglioneuroblastoma in at least one site present at
                       time of enrollment is required to be obtained.

                    2. MIBG non avid tumors: These patients require a biopsy done at any time prior
                       to enrollment confirming neuroblastoma and/or ganglioneuroblastoma in at
                       least one soft tissue site (even if FDG-PET avid) present at the time of
                       enrollment.

          -  At least one non-target soft tissue lesion that is not measurable, but had a biopsy
             positive for neuroblastoma and/or ganglioneuroblastom or is MIBG avid at any time
             prior to enrollment.

          -  Patients must have a life expectancy of at least 12 weeks and a Lansky (≤16 years) or
             Karnofsky (>16 years) score of at least 50.

          -  Prior Therapy

               1. Patients must have fully recovered from the acute toxic effects of all prior
                  chemotherapy, immunotherapy, or radiotherapy prior to study registration.

               2. Patients must not have received the therapies indicated below after disease
                  evaluation or within the specified time period prior to registration on this
                  study as follows:

                    1. Myelosuppressive chemotherapy: must not have received within 2 weeks prior
                       to registration.

                    2. Biologic anti-neoplastics- agents not known to be associated with reduced
                       platelet or ANC counts (including retinoids): must not have received within
                       7 days prior to registration.

                    3. Monoclonal antibodies: must have received last dose at least 7 days or 3
                       half-lives whichever is longer, but no longer than 30 days (with recovery of
                       any associated toxicities), prior to protocol therapy.

                    4. Cellular Therapy (e.g. modified T cells, NK cells, dentritic cells etc.):
                       must not have received within 3 weeks and resolution of all toxicities.

                    5. Radiation: must not have received small port radiation within 7 days prior
                       to registration.

                    6. Hematopoietic Stem Cell Transplant:

                    7. IVIG

          -  All patients must have adequate organ function defined as:

          -  Hematological Function:

               1. Absolute Phagocyte count (APC= neutrophils and monocytes): ≥ 1000/µL

               2. Absolute Neutrophil count: ≥750/µL

               3. Absolute Lymphocyte count ≥ 500/µL

               4. Platelet count: ≥ 50,000/µL, transfusion independent (no platelet transfusions
                  within 1 week)

               5. Hemoglobin ≥ 10 g/dL (may transfuse)

               6. Patients with known bone marrow metastatic disease will be eligible for study as
                  long as they meet hematologic function criteria above.

          -  Renal Function: Age-adjusted serum creatinine ≤ to 1.5 x normal for age/gender OR
             creatinine clearance or GFR greater than or equal to 60 cc/min/1.73m2

          -  Liver Function: Total bilirubin ≤ 1.5 x normal for age, AND SGPT (ALT) 135 and SGOT
             (AST) ≤ 3 x upper limit of normal. Sinusoidal obstruction syndrome (SOS) if present,
             must be stable or improving clinically

          -  Cardiac Function: Normal ejection fraction documented by either echocardiogram or
             radionuclide MUGA evaluation OR Normal fractional shortening documented by
             echocardiogram

          -  Pulmonary Function: No dyspnea at rest, no oxygen requirement.

          -  Reproductive Status: All post-menarchal females must have a negative beta-HCG. Males
             and females of reproductive age and childbearing potential must use effective
             contraception for the duration of their participation.

          -  Patients with other ongoing serious medical issues must be approved by the study chair
             prior to registration.

          -  Patients may not receive any other anti-cancer agents or radiotherapy while on
             protocol therapy.

          -  Ability to Swallow Pills

        Exclusion Criteria:

          -  Pregnancy: Quantitative Serum B-HCG must be negative in girls who are post-menarchal.

          -  Breast feeding women are not eligible.

          -  Active or uncontrolled infection

          -  CNS metastasis.

          -  Hypersensitivity to thalidomide, including history of erythema nodosum if
             characterized by a desquamating rash while taking thalidomide or similar drugs (dose
             level 4 only).

          -  Patient declines participation in NANT 2004-05; unless the institution has been
             granted special exemption from mandatory registration on NANT 2004-05 by the NANT
             Operations Center.